Adenosine Injection Articles

FDA clears Akorn's ANDA for adenosine inj

10 November 2008

King's profit drops 34% in 2nd-qtr 2008 to $43M

18 August 2008

Japan stock market week to June 30, 2008

7 July 2008

Astellas' fiscal 06/07 first-half net sales rise 5%

20 November 2006

CV Thera/Astellas's regadenoson meets Ph III endpoint

22 August 2005

Japan stock market week to June 20

27 June 2005

Fujisawa's 9-month sales rise 2.5%

21 February 2005

Aspirations of Astellas Pharma, the merged Yamanouchi/Fujisawa

22 November 2004

Daiichi sees first-half revenues fall 2%

15 November 2004

Tokyo pharma stocks - week to October 25

1 November 2004

Fujisawa fiscal 1st qtr 2005 sales dip 0.5%

16 August 2004

Fujisawa net income leaps 44.8%, despite only 3.5% sales growth

10 May 2004

Fujisawa sales soar in North America

12 November 2001

King Pharmaceuticals 2nd-qtr earnings leap 77%

25 July 2001

Fujisawa net income slides 10.4% as R&D investment increases

21 May 2001

Medco Adenoscan follow-up to enter clinic

11 February 1999

Fujisawa Reports Steady Interim Growth

11 November 1998

Fujisawa Restructuring In The USA, Revises Forecasts

31 March 1998

88% Increase In EPS For 3rd Qtr At Medco

15 October 1997

Adenoscan In Japan

26 June 1997

Fujisawa gets order for Adenoscan

7 August 1995

Gensia Launches Arbutamine In UK

12 June 1995

UK Approval For Adenoscan

12 June 1995

Medco terminates Adenoscan agreement with Abbott

5 June 1995

Medco's Adenoscan Approved By FDA

29 May 1995

Medco's Adenoscan Approved By FDA

29 May 1995

Fujisawa USA/Medco Settle Adenoscan Lawsuits

29 May 1995

MEDCO RECEIVES APPROVAL FROM FDA

10 January 1994

FUJISAWA INELIGIBLE FOR FDA APPROVALS

17 May 1993

Showing 1-29 of 29 articles

Go to beginningPrevious
  • 1
NextGo to end